Mentoring patient-oriented researchers in pediatric diarrhea

指导以患者为中心的小儿腹泻研究人员

基本信息

  • 批准号:
    10591728
  • 负责人:
  • 金额:
    $ 17.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-11 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary Diarrheal illness is the second most common cause of non-neonatal death among young children worldwide, and is a major cause of morbidity. Current etiologic diagnosis of diarrhea relies on microbial detection, and decisions for antibiotics commonly empiric. However, the majority of cases of diarrhea do not benefit from antibiotic use, and testing for all potential pathogens is neither financially nor logistically feasible. Thus, methods to improve the clinical management of pediatric diarrheal illness, including strategies for antimicrobial and diagnostic stewardship, are needed. Clinical prediction rules are potential tools to address this need, and in this K24 application, our overall goal is to explore strategies to improve clinical decision-making for diarrhea management, through use of spatial-temporal data and biomarkers. Dr. Leung, the PI, is a physician-scientist with training in clinical infectious diseases, immunology, microbiology, and epidemiology, with a focus on enteric infections, especially those that cause diarrheal illness in children in limited-resource settings. He has mentored over 40 patient-oriented researchers (PORs) since the start of his independent research program in 2014; additionally, he has co-mentored numerous PORs in collaboration with scientists and clinicians working in low- and middle-income countries. Leveraging infrastructure already in place from three ongoing NIH-funded awards (R01AI130378, R01AI135114, R01AI135115), as well as Gates Foundation-funded studies, he proposes to augment his current POR by addressing the following aims: 1) To examine the use of spatial- temporal data for individual-level clinical prediction of pediatric diarrhea, where the use of A) serosurveillance, B) molecular diagnostic, and C) earth observation-derived data will be explored, and 2) To identify clinical use- cases, and potential candidates, of fecal biomarkers that complement clinical decision support tools for management of pediatric diarrhea, using both qualitative methods to examine end-user perspectives and identify use-cases, and metabolomics and transcriptomics methods to identify candidate biomarkers. To accomplish these aims, he has established a co-mentoring team of experienced investigators with diverse expertise in statistical methods, biomarker discovery, and mentoring of POR investigators. This award will provide protected time for Dr. Leung to improve and increase his mentoring capacity of POR trainees, expand his expertise and experience in bioinformatics, and generate data for future projects to improve the management and knowledge of pediatric diarrheal infections.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Ted Leung其他文献

Daniel Ted Leung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Ted Leung', 18)}}的其他基金

Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    10522523
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    10132972
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    9912094
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    10649542
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    9912093
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    10388296
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    10153667
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    9926810
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    9398501
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Immune responses to Vibrio cholerae in children
儿童对霍乱弧菌的免疫反应
  • 批准号:
    8517006
  • 财政年份:
    2012
  • 资助金额:
    $ 17.19万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了